Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (198)

« Back to Publications

Navigating through uncertainty-Experience from the UK national VEXAS MDT.

Pietsch D. et al, (2026), British journal of haematology, 208, 1306 - 1313

The invasive non-typhoidal Salmonella vaccine landscape: Innovations and challenges ahead.

Revie NM. et al, (2026), Vaccine, 76

The age-specific concentrations and seroprevalence of antibodies against Salmonella Enteritidis (O:9) and Salmonella Typhimurium (O:4,5) across three sites in Kenya.

Muthumbi EM. et al, (2026), The Journal of infectious diseases

Lessons from COVID-19: the 100 Days Mission and antimicrobial resistance

Hatchett R. and MacLennan CA., (2026), Philosophical Transactions B, 381

Vaccines and antimicrobial resistance: from science to policy—summary and outcomes

MacLennan CA. et al, (2026), Philosophical Transactions B, 381

Vaccines and antimicrobial resistance: from science to policy—introduction

MacLennan CA. and Davies S., (2026), Philosophical Transactions B, 381

The immunology of infection

Gilchrist JJ. et al, (2026), Medicine United Kingdom, 54, 1 - 8

Estimating the economic burden of invasive non-typhoidal Salmonella infections in low- and middle-income countries.

Lee J-S. et al, (2025), BMJ global health, 10

Cross-comparison study of three ELISA methodologies to measure Shigella Sonnei O-antigen serum IgG.

Stickings P. et al, (2025), mSphere, 10

Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations.

Excler J-L. et al, (2025), Vaccine, 62

Treatment outcomes in patients with VEXAS syndrome: a retrospective cohort study.

Al-Hakim A. et al, (2025), The Lancet. Rheumatology, 7, e472 - e484

The TyphiNET data visualisation dashboard: unlocking Salmonella Typhi genomics data to support public health

Dyson ZA. et al, (2025), Genome Medicine, 17

Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation.

Emary K. et al, (2025), Vaccine, 55

BactiVac, the Bacterial Vaccines Network.

MacLennan CA. et al, (2025), Vaccine, 57

Consultation report - considerations for a regulatory pathway for bivalent Salmonella Typhi/Paratyphi A vaccines for use in endemic countries.

Ibarz-Pavon AB. et al, (2025), Vaccine, 56

Load More

1
2
3
4
5
6
7
...
»